Eight analysts raise Sobi targets, but three stay below the share price
BioStock's consensus review of Sobi: all eight houses lifted targets after the Q3 report, yet three still sit under the current share price.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
All eight analyst houses covering Sobi raised their price targets after the third-quarter report, according to BioStock, whose review appears on TradingView. Revenue reached 9,124 million SEK, up 16% at constant exchange rates, and the company lifted its 2026 guidance.
The median target of 527.5 SEK sits 5.9% above the 498.20 SEK close on 6 November. Opinions still diverge: five Buy-rated firms see 5.4% to 20.4% upside, while three Hold-rated firms, Danske Bank, Nordea and DNB Carnegie, place targets 2.9% to 4.7% below the price. Pareto was the lone firm to upgrade its rating, moving from Hold to Buy.
why it matters
The spread in estimates shows how quickly views can change: Nordea cut its target and downgraded to Hold the week before the report, then raised it to 480 SEK afterwards. Upcoming catalysts could shift estimates again, including detailed phase III data on pozdeutinurad in gout at ACR Convergence on 11 November, an EU decision on Tryngolza expected in Q4, and CEO Guido Oelkers' departure by the end of January 2027.
tags
instruments
sources
- BioStock publishes Consensus Analysis for Sobi: eight revisions, eight raised targets — TradingView, 9 November 2026 at 07:53 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗